Researchers at MIT and Massachusetts General Hospital have designed an expanding pill that can be easily swallowed but can remain in the stomach potentially for months without obstructing normal gastrointestinal function.
Folding DNA into new, functional shapes isn't a new technique, but researchers at Arizona State University have demonstrated novel design methods that allow them an amount of control over the genetic substance never seen before, creating new three-dimensional shapes that could ultimately be used in drug delivery.
The board of governors at the Patient-Centered Outcomes Research Institute has signed off on an $142.5 million investment in PCORnet, an attempt to mine ever-growing repositories of health and clinical data for research.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.
Though it can boast its ownership of the world's bestselling vaccine in Prevnar, Pfizer is not stopping there. On Tuesday, the New York City-based pharma unveiled details of its effort to build out its vaccines business by researching a range of conditions from birth until old age.
Purdue University researchers are developing a "smart" capsule to deliver drugs directly to the large intestine, bypassing the stomach and small intestine. It could have application to the treatment of irritable bowel syndrome, Crohn's disease and fighting the life-threatening bacteria Clostridium difficile, all conditions that affect the large intestine.
Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.
Vermillion has tapped investors for money to fund the enhancement of its bioinformatics platform. The diagnostics and bioanalytics player pulled in a total of $18.8 million through a stock offering, a slice of which will be ploughed into biotech IT.
Illumina has introduced a suite of tools and software to help research organizations new to population-scale sequencing to get started with its HiSeq X Ten and Five systems. The move comes one month after BGI joined the large-scale sequencing field with a package that covers each step of the process, from sample preparation to data analysis.